vs
Side-by-side financial comparison of Jazz Pharmaceuticals plc (JAZZ) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Jazz Pharmaceuticals plc is the larger business by last-quarter revenue ($1.2B vs $708.5M, roughly 1.7× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 17.0%, a 2.1% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 10.1%). Jazz Pharmaceuticals plc produced more free cash flow last quarter ($345.8M vs $188.1M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 15.2%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
JAZZ vs MEDP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $708.5M |
| Net Profit | $203.5M | $135.1M |
| Gross Margin | — | — |
| Operating Margin | 21.2% | 21.6% |
| Net Margin | 17.0% | 19.1% |
| Revenue YoY | 10.1% | 32.0% |
| Net Profit YoY | 6.5% | 15.5% |
| EPS (diluted) | $3.34 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2B | $708.5M | ||
| Q3 25 | $1.1B | $659.9M | ||
| Q2 25 | $1.0B | $603.3M | ||
| Q1 25 | $897.8M | $558.6M | ||
| Q4 24 | $1.1B | $536.6M | ||
| Q3 24 | $1.1B | $533.3M | ||
| Q2 24 | $1.0B | $528.1M | ||
| Q1 24 | $902.0M | $511.0M |
| Q4 25 | $203.5M | $135.1M | ||
| Q3 25 | $251.4M | $111.1M | ||
| Q2 25 | $-718.5M | $90.3M | ||
| Q1 25 | $-92.5M | $114.6M | ||
| Q4 24 | $191.1M | $117.0M | ||
| Q3 24 | $215.1M | $96.4M | ||
| Q2 24 | $168.6M | $88.4M | ||
| Q1 24 | $-14.6M | $102.6M |
| Q4 25 | 21.2% | 21.6% | ||
| Q3 25 | 5.1% | 21.5% | ||
| Q2 25 | -65.6% | 20.9% | ||
| Q1 25 | -6.2% | 20.3% | ||
| Q4 24 | 17.5% | 23.4% | ||
| Q3 24 | 24.7% | 21.1% | ||
| Q2 24 | 19.5% | 19.9% | ||
| Q1 24 | 7.3% | 20.4% |
| Q4 25 | 17.0% | 19.1% | ||
| Q3 25 | 22.3% | 16.8% | ||
| Q2 25 | -68.7% | 15.0% | ||
| Q1 25 | -10.3% | 20.5% | ||
| Q4 24 | 17.6% | 21.8% | ||
| Q3 24 | 20.4% | 18.1% | ||
| Q2 24 | 16.5% | 16.7% | ||
| Q1 24 | -1.6% | 20.1% |
| Q4 25 | $3.34 | $4.65 | ||
| Q3 25 | $4.08 | $3.86 | ||
| Q2 25 | $-11.74 | $3.10 | ||
| Q1 25 | $-1.52 | $3.67 | ||
| Q4 24 | $2.97 | $3.67 | ||
| Q3 24 | $3.42 | $3.01 | ||
| Q2 24 | $2.49 | $2.75 | ||
| Q1 24 | $-0.23 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | $497.0M |
| Total DebtLower is stronger | $5.4B | — |
| Stockholders' EquityBook value | $4.3B | $459.1M |
| Total Assets | $11.7B | $2.0B |
| Debt / EquityLower = less leverage | 1.24× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.4B | $497.0M | ||
| Q3 25 | $1.3B | $285.4M | ||
| Q2 25 | $1.2B | $46.3M | ||
| Q1 25 | $1.9B | $441.4M | ||
| Q4 24 | $2.4B | $669.4M | ||
| Q3 24 | $2.2B | $656.9M | ||
| Q2 24 | $1.4B | $510.9M | ||
| Q1 24 | $1.4B | $407.0M |
| Q4 25 | $5.4B | — | ||
| Q3 25 | $5.4B | — | ||
| Q2 25 | $5.4B | — | ||
| Q1 25 | $5.4B | — | ||
| Q4 24 | $6.1B | — | ||
| Q3 24 | $6.1B | — | ||
| Q2 24 | $5.7B | — | ||
| Q1 24 | $5.7B | — |
| Q4 25 | $4.3B | $459.1M | ||
| Q3 25 | $4.0B | $293.6M | ||
| Q2 25 | $3.7B | $172.4M | ||
| Q1 25 | $4.2B | $593.6M | ||
| Q4 24 | $4.1B | $825.5M | ||
| Q3 24 | $4.2B | $881.4M | ||
| Q2 24 | $3.8B | $763.6M | ||
| Q1 24 | $3.7B | $671.5M |
| Q4 25 | $11.7B | $2.0B | ||
| Q3 25 | $11.4B | $1.8B | ||
| Q2 25 | $10.9B | $1.6B | ||
| Q1 25 | $11.5B | $1.9B | ||
| Q4 24 | $12.0B | $2.1B | ||
| Q3 24 | $12.3B | $2.1B | ||
| Q2 24 | $11.4B | $1.9B | ||
| Q1 24 | $11.3B | $1.8B |
| Q4 25 | 1.24× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | 1.29× | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 1.47× | — | ||
| Q2 24 | 1.52× | — | ||
| Q1 24 | 1.54× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $362.5M | $192.7M |
| Free Cash FlowOCF − Capex | $345.8M | $188.1M |
| FCF MarginFCF / Revenue | 28.9% | 26.6% |
| Capex IntensityCapex / Revenue | 1.4% | 0.6% |
| Cash ConversionOCF / Net Profit | 1.78× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $1.3B | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $362.5M | $192.7M | ||
| Q3 25 | $474.6M | $246.2M | ||
| Q2 25 | $88.9M | $148.5M | ||
| Q1 25 | $429.8M | $125.8M | ||
| Q4 24 | $398.6M | $190.7M | ||
| Q3 24 | $398.7M | $149.1M | ||
| Q2 24 | $331.4M | $116.4M | ||
| Q1 24 | $267.2M | $152.7M |
| Q4 25 | $345.8M | $188.1M | ||
| Q3 25 | $459.4M | $235.5M | ||
| Q2 25 | $75.9M | $142.4M | ||
| Q1 25 | $415.9M | $115.8M | ||
| Q4 24 | $385.3M | $183.0M | ||
| Q3 24 | $388.0M | $138.5M | ||
| Q2 24 | $324.3M | $103.5M | ||
| Q1 24 | $260.3M | $147.2M |
| Q4 25 | 28.9% | 26.6% | ||
| Q3 25 | 40.8% | 35.7% | ||
| Q2 25 | 7.3% | 23.6% | ||
| Q1 25 | 46.3% | 20.7% | ||
| Q4 24 | 35.4% | 34.1% | ||
| Q3 24 | 36.8% | 26.0% | ||
| Q2 24 | 31.7% | 19.6% | ||
| Q1 24 | 28.9% | 28.8% |
| Q4 25 | 1.4% | 0.6% | ||
| Q3 25 | 1.3% | 1.6% | ||
| Q2 25 | 1.2% | 1.0% | ||
| Q1 25 | 1.5% | 1.8% | ||
| Q4 24 | 1.2% | 1.4% | ||
| Q3 24 | 1.0% | 2.0% | ||
| Q2 24 | 0.7% | 2.4% | ||
| Q1 24 | 0.8% | 1.1% |
| Q4 25 | 1.78× | 1.43× | ||
| Q3 25 | 1.89× | 2.22× | ||
| Q2 25 | — | 1.65× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | 2.09× | 1.63× | ||
| Q3 24 | 1.85× | 1.55× | ||
| Q2 24 | 1.97× | 1.32× | ||
| Q1 24 | — | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
